This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

OIPE
OCT 07 2002
PATENT & TRADEMARK OFFICE

059

#8

LAHIVE & COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DiGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS *
LISA M. DiROCCO
HATHAWAY P. RUSSELL **
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

October 3, 2002

COPY 3 of 3

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 10/010942
For: *Humanized Antibodies That Recognize Beta Amyloid Peptide*
Inventors: Basi, Guriq, *et al.*
Filed: December 6, 2001
Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. ~~Information Disclosure Statement;~~
2. PTO Form PTO/SB/08A;
3. Copies of references cited in PTO Form PTO/SB/08A (325); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

October 3, 2002
Date

Debra J. Milasincic, Esq., Reg. No. 46,931

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

OIPE
OCT 07 2002
JC55
PATENT & TRADEMARK OFFICE

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Basi, Guriq, *et al.*

Serial No.: 10/010942

Filed: December 6, 2001

For: *Humanized Antibodies That Recognize Beta Amyloid Peptide*

Attorney Docket No.: ELN-002

Group Art Unit: 1645

Examiner: Not Yet Assigned

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

October 3, 2002
Date of Signature and of Mail Deposit

By: _____
Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per*

OIPE
OCT 07 2002
PATENT & TRADEMARK OFFICE

as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00;
09/723,927 filed 11/28/00;
09/723,762 filed 11/28/00;
09/724,102 filed 11/28/00;
09/724,489 filed 11/28/00;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00;
09/724,495 filed 11/27/00;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00;
09/724,961 filed 11/28/00;
09/580,018 filed 05/26/00;
09/724,552 filed 11/28/00;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00;
09/724,288 filed 11/28/00;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
09/585,817 filed 06/01/00;

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

OIPE JC55 OCT 07 2002 PATENT & TRADEMARK OFFICE

RECEIVED OCT 10 2002 TECH CENTER 1600/2900

09/724,567 filed 11/28/00;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00;

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

09/724,570 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/04/02 (U.S. National Stage of PCT/US00/15239 filed 06/01/00); and,
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00).

Applicant further cites the following commonly owned expired provisional applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and,
60/251,892 filed 12/06/00.

Solomon Reissue

The Assignees of the instant application are licensees of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Patent No. 5,688,651 and U.S. Application No. 09/441,140 are cited in the PTO/SB/08A form attached hereto.

OIPE JC55 OCT 07 2002 PATENT & TRADEMARK OFFICE

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Raso Grant Application

Applicants wish to bring to the Examiner's attention a grant application believed to have been submitted by Victor Raso for NIH Grant 1 R43 AGI 5746-01 on August 29, 1997. Cite no. 144 is a redacted version of the grant proposal and cite no. 304 is an unredacted version. Applicants obtained copies of this grant proposal under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998 (the funding date), but the exact date of public accessibility, if any, is not known to Applicants.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: October 3, 2002
AEM/DJM/CEH/ipc
Enclosures

OIPE JC53 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	283	09/441,140		Solomon et al.	11-16-1999	
	242	60/168,594		Chalifour et al.	N/A	
	282	60/169,687		Chain	N/A	
	295	60/184,601		Holtzman et al.	N/A	
	299	60/186,295		Rasmussen et al.	N/A	
	296	60/254,465		Holtzman et al.	N/A	
	297	60/254,498		Holtzman et al.	N/A	
	300	2001/0018053	A1	McMichael	08-30-2001	
	267	6,294,171	B2	McMichael	09-25-2001	
	234	6,284,221	B1	Schenk, et al.	09-04-2001	
	230	6,262,335	B1	Hsiao et al.	07-17-2001	
	231	6,114,133		Seubert et al.	09-05-2000	
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	221	5,989,566		Cobb et al.	11-23-1999	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	09-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findeis et al.	12-29-1998	
	9	5,851,996		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio e al.	11-17-1998	
	12	5,786,180		Konig et al.	07-28-1998	
	207	5,780,587		Potter	07-14-1998	
	13	5,753,624		McMichael et al.	05-19-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	197	5,744,368		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
	17	5,679,348		Nesburn et al.	10-21-1997	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	18	5,645,820		Hafler et al.	07-08-1997	
	19	5,641,474		Hafler et al.	06-24-1997	
	20	5,641,473		Hafler et al.	06-24-1997	
	21	5,612,486		McConlogue et al.	03-18-1997	
	22	5,605,811		Seubert et al.	02-25-1997	
	23	5,585,100		Mond et al.	12-17-1996	
	24	5,571,500		Hafler et al.	11-05-1996	
	25	5,571,499		Hafler et al.	11-05-1996	
	175	5,441,870		Seubert, et al.	08-15-1995	
	26	5,434,170		Andrulis, Jr.	07-18-1995	
	27	5,387,742		Cordell	02-07-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	284	5,231,170		Averback	1993-07-27	
	28	5,231,000		Majocha et al.	07-27-1993	
	29	5,220,013		Ponte et al.	06-15-1993	
	30	5,208,036		Eppstein et al.	05-04-1993	
	31	5,192,753		McGeer et al.	03-09-1993	
	32	5,187,153		Cordell et al.	02-16-1993	
	33	5,057,540		Kensil et al.	10-15-1991	
	198	5,004,697		Pardridge	04-0201991	
	34	4,666,829		Glenner et al.	05-19-1987	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Office[3]	Number[4]	Kind Code[5] (*if known*)				
	35	EP	911 036	A2		04-28-1999		
	36	EP	868 918	A2		10-07-1998		
	37	EP	863 211	A1		09-09-1998		
	38	EP	845 270	A1		06-03-1998		
	39	EP	782 859	A1		07-09-1997		
	40	EP	683 234	A1		11-22-1995		
	41	EP	666 080	A1		08-09-1995		
	42	EP	652 962	B1		12-16-1998		
	43	EP	639 081	B1		11-03-1999		
	44	EP	613 007	A2		08-31-1994		
	45	EP	594 607	B1		08-27-1997		
	46	EP	561 087	B1		08-04-1999		
	47	EP	526 511	B1		05-28-1997		
	48	EP	506 785	B1		03-15-2000		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC55
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	49	EP	451 700	A1		10-16-1991		
	50	EP	440 619	B1		01-24-1996		
	51	EP	359 783	B1		11-29-1995		
	52	EP	276 723	B1		12-08-1993		Yes
	187	EP	783 104	A1		07-09-1997		
	294	PCT	01/62801	A2		08-30-2001		
	301	PCT	01/62284	A2		03-01-2000		
	298	PCT	01/42306	A2		06-14-2001		
	243	PCT	01/39796	A2		06-07-2001		
	199	PCT	00/77178	A1		12-21-2000		
	240	PCT	00/43039	A1		07-27-2000		
	188	PCT	00/43049	A1		07-27-2000		
	53	PCT	99/60024	A1		11-25-1999		
	54	PCT	99/60021	A2		11-15-1999		
	55	PCT	99/58564	A1		11-18-1999		
	56	PCT	99/06066	A2		02-11-1999		
	57	PCT	99/27949	A1		06-10-1999		
	58	PCT	99/27944	A1		06-10-1999		
	59	PCT	99/27911	A1		06-10-1999		
	203	PCT	99/00150	A2		01-07-1999		
	60	PCT	98/44955	A1		10-15-1998		
	61	PCT	98/07850	A2		02-26-1998		
	202	PCT	97/21728	A1		06-19-1997		
	62	PCT	97/17613	A1		05-15-1997		
	63	PCT	96/39176	A1		12-12-1996		
	208	PCT	96/28471	A1		09-19-1996		
	64	PCT	96/25435	A1		08-22-1996		
	65	PCT	96/18900	A1		06-20-1996		
	66	PCT	95/31996	A1		11-30-1995		
	200	PCT	95/12815	A1		05-11-1995		
	67	PCT	95/11994	A1		05-04-1995		
	68	PCT	95/11311	A1		04-27-1995		
	227	PCT	95/11008	A2		04-27-1995		
	69	PCT	95/05853	A1		03-02-1995		
	70	PCT	95/04151	A2		02-09-1995		
	201	PCT	94/28412	A1		12-08-1994		
	71	PCT	94/03615	A1		02-17-1994		
	72	PCT	94/01772	A1		01-20-1994		
	73	PCT	93/21950	A1		11-11-1993		
	74	PCT	93/16724	A1		09-02-1993		
	75	PCT	93/15760	A1		08-19-1993		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

OIPE JC655 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	76	PCT	93/14200	A1		07-22-1993		
	205	PCT	93/04194	A1		03-04-1993		
	77	PCT	93/02189	A1		02-04-1993		
	78	PCT	92/13069	A1		08-06-1992		
	79	PCT	92/06708	A1		04-30-1992		
	80	PCT	92/06187	A1		04-16-1992		
	81	PCT	91/19810	A1		12-26-1991		
	82	PCT	91/16819	A1		11-14-1991		
	83	PCT	91/12816	A1		09-05-1991		
	84	PCT	91/08760	A1		06-27-1991		
	85	PCT	90/12871	A1		11-01-1990		
	86	PCT	90/12870	A1		11-01-1990		
	87	PCT	89/01343	A1		02-23-1989		
	88	PCT	89/06242	A1		07-13-1989		
	89	PCT	89/06689	A1		07-27-1989		
	90	PCT	89/03687	A1		05-05-1989		
	91	PCT	88/10120	A1		12-29-1988		
	92	GB	2 220 211	A		01-04-1990		
	93	GB	2 335 192	A		09-15-1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC55 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Guriq, Basi *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).	☐
	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95).	☐
	176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000).	☐
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992).	
	96	BAUER et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).	☐
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999).	
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992).	
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).	☐
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).	☐
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19: 939-945 (1997).	☐
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 (1993).	☐
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).	☐
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992).	
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT & TRADEMARK OFFICE
OCT 07 2002
JC555

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993).	☐
	266	CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000).	
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991).	
	302	CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999).	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).	
	286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).	
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993).	
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).	
	214	DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001).	
	220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. – comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)	
	103	DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995).	
	288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001).	
	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	
	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	
	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983).	
	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm, Sci., 22:2-3 (2001).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC55 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 15 2002 TECH CENTER 1600 2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).	
	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).	
	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).	
	108	FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).	
	246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001).	
	247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).	
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998).	
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).	
	244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000).	
	210	FRIEDLAND et al., ""Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994).	
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514): 523-527 (1995).	
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science 920:274-84 (2000).	
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992).	
	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).	
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1186 (1993).	
	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999).	
	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC53 OCT 07 2002 PATENT & TRADEMARK OFFICE

RECEIVED OCT 15 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	112	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998).	
	114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984).	
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994).	
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).	
	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 93:149-153 (1998).	
	237	GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS USA, 93:427-432 (1996).	
	190	GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995).	
	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000).	
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997).	
	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).	
	118	HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993).	
	182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	
	119	HANES et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28: 97-119 (1997).	
	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).	
	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).	
	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).	
	193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC555 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 15 2002 Technology Center 2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).	
	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000).	
	236	HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991).	
	122	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1996).	
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).	
	174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).	
	256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987).	
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989).	
	192	IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994).	
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982).	
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997).	
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-384 (1991).	
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).	
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996).	
	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).	
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995).	
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).	
	130	LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).	
	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997).	
	132	LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	
	260	LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000).	
	184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997).	
	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997).	
	134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991).	
	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992).	
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994).	
	263	MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $Aβ_{42(43)}$," Annals of Neurology, 40:149-156 (1996).	
	262	MANN; et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	
	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985).	
	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997).	
	264	McGeer, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992).	
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998).	
	136	MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 17 2002 TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	265	Mena, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995).	
	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991).	
	206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992).	
	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).	
	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995).	
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).	
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998).	
	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997).	
	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965).	
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987).	
	140	PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).	
	141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," Eur. J. Immunol., 25: 3521-3524 (1995).	
	232	PETERSON, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996).	
	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996).	
	142	PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994).	
	143	QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	145	RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (April 2, 1998).	
	144	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
	304	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
	146	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).	
	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).	
	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993).	
	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994).	
	279	SAITO et al., "Vector-mediated delivery of ^{125}I-labeled β-amyloid peptide Ab^{1-40} through the blood-brain barrier and binding to Alzheimer disease amyloid of the $A\beta^{1-40}$ vector complex," PNAS USA, 92:10227-10231 (1995).	
	278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991).	
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997).	
	148	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999).	
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995).	
	270	SCHENK, et al., "β-peptide immunization," Arch. Nuerol., 57:934-936 (2000).	
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994).	
	151	SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10): 403-409 (1993).	
	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).	
	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC55 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," Scientific American, pgs. 68-78 (November, 1991).	
	153	SELKOE, Dennis J., "In the Beginning...," Nature, 354:432-433 (1991).	
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).	
	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992).	
	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).	
	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," Vet. Quart., 19(3): 101-105 (1997).	
	185	SOLOMON and GOLDSTEIN, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996).	
	186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	
	159	SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS USA, 94:4109-4112 (1997).	
	160	SOLOMON et al., "Monoclonal antibodies inhibit in *vitro* fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS USA, 93:452-455 (1996).	
	161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	
	162	SOLOMON, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).	
	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996).	
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).	
	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium Falciparum* Malaria", N. Engl. J. Med., 336(2): 86-91 (1997).	
	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997).	
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on *in vitro* properties of the amyloid β-peptide as modeled with *N*-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996).	
	165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000).	
	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996).	
	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).	
	167	VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994).	
	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994).	
	169	WALKER et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).	
	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000).	
	171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).	
	172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin. Neurobiol., 7: 695-700 (1997).	
	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998).	
	170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-872 (2000).	
	223	Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)	
	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," PNAS USA, 82:8729-8732 (1985).	
	173	WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS USA, 94: 1550-1555 (1997).	
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997).	
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998).	
	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC35
OCT 07 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	A1	Chen G, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):975-9	
	A2	Janus C, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):979-82	
	A3	Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997 Oct;77(4):1081-132	
	A4	Merluzzi S, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 2000 Apr;4(2):77-85.	
	A5	Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):982-5	
	A6	Schenk D, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 2001 Nov;20(11):679-81	
	A7	Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998 Nov;8(11):447-53	
	A8	Sigurdsson EM, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 2000 Jan;59(1):11-17	
	A9	Sinha S, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 2000;920:206-8	
	A10	Soto C, et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998 Jul;4(7):822-6	
	A11	Vehmas AK, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. 2001 Nov;20(11):713-21	

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A12	5,593,846		Schenk et al.	01-14-1997	
	A13	5,837,672		Schenk et al.	11-17-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A14		WO 00/72876	A2, A3		12-07-2000		
	A15		WO 00/72880	A2, A3		12-07-2000		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC535 OCT 07 2002 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

	B1	Du Y, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001 Sep 11;57(5):801-5.	
	B2	Small DH, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001 Aug;2(8):595-8	

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B3	US 2001/0102261	A1	Raso	08-01-2002	
	B4	US 2002/0136718	A1	Raso	09-26-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B5		WO 00/77178	A1		12-21-2000		

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B6	09/724,842		Chalifour et al.	N/A	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.